The DNA Damaging Revolution: PARP Inhibitors and Beyond
- PMID: 31099635
- DOI: 10.1200/EDBK_238473
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Abstract
Cancer-specific DNA repair defects are abundant in malignant tissue and present an opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data demonstrated the concept of synthetic lethality between BRCA genetic defects and pharmacologic PARP inhibition, suggesting that there may be monotherapy activity with this class of agents and supporting the early trial testing of this molecularly driven approach. Although the first foray into the clinic for PARP inhibitors was in combination with DNA-damaging cytotoxic agents, clinical development was limited by the more-than-additive toxicity, in particular dose-limiting myelosuppression. As more tolerable single agents, PARP inhibitors are now approved for the treatment of ovarian cancer in different settings and BRCA-mutant breast cancers. Beyond PARP inhibitors, there is now a large armamentarium of potent and relatively selective inhibitors in clinical trial testing against key targets involved in the DNA damage response (DDR), including ATR, ATM, CHK1/2, WEE1, and DNA-PK. These agents are being developed for patients with molecularly selected tumors and in rational combinations with other molecularly targeted agents and immune checkpoint inhibitors. We detail the clinical progress made in the development of PARP inhibitors, review rational combinations, and discuss the development of emerging inhibitors against novel DDR targets, including DNA repair proteins, DNA damage signaling, and DNA metabolism.
Similar articles
-
Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Curr Treat Options Oncol. 2020 Jun 29;21(8):62. doi: 10.1007/s11864-020-00763-7. Curr Treat Options Oncol. 2020. PMID: 32601814 Free PMC article. Review.
-
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16. Cancer. 2018. PMID: 29660759 Free PMC article. Review.
-
Targeting DNA repair and replication stress in the treatment of ovarian cancer.Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22. Int J Clin Oncol. 2017. PMID: 28643177 Review.
-
DNA damage response as a therapeutic target in gynecological cancers.Curr Opin Oncol. 2016 Sep;28(5):404-11. doi: 10.1097/CCO.0000000000000320. Curr Opin Oncol. 2016. PMID: 27455135
-
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Cancer Discov. 2017. PMID: 28003236 Free PMC article. Review.
Cited by
-
Development of PARP inhibitors in advanced prostate cancer.Ther Adv Med Oncol. 2024 Jan 9;16:17588359231221337. doi: 10.1177/17588359231221337. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38205078 Free PMC article. Review.
-
Drug antagonism and single-agent dominance result from differences in death kinetics.Nat Chem Biol. 2020 Jul;16(7):791-800. doi: 10.1038/s41589-020-0510-4. Epub 2020 Apr 6. Nat Chem Biol. 2020. PMID: 32251407 Free PMC article.
-
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.Cancers (Basel). 2021 Aug 31;13(17):4405. doi: 10.3390/cancers13174405. Cancers (Basel). 2021. PMID: 34503215 Free PMC article.
-
Molecular Subtyping and Precision Medicine for Pancreatic Cancer.J Clin Med. 2021 Jan 4;10(1):149. doi: 10.3390/jcm10010149. J Clin Med. 2021. PMID: 33406790 Free PMC article. Review.
-
Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes.Front Oncol. 2022 Oct 26;12:1019798. doi: 10.3389/fonc.2022.1019798. eCollection 2022. Front Oncol. 2022. PMID: 36387226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
